IDEV Technologies Announces European Launch of SUPERA VERITAS(TM) Stent Delivery System

Innovative Technology Provides Precision, Ease of Use For Delivery of SUPERA(R) Stent

WEBSTER, Texas, May 18, 2010 - IDEV Technologies, Incorporated, (IDEV) an emerging leader in the
development and marketing of minimally invasive medical technologies, today
announced the European launch of the SUPERA VERITAS(TM) Peripheral Vascular
System, a novel and innovative stent delivery system designed to be reliable,
easy to use and precise. The SUPERA VERITAS system was formally launched in
the first quarter of 2010 at the Leipzig Interventional Course (LINC) 2010
conference in Leipzig, Germany. The LINC conference is dedicated to advancing
clinical solutions for patients with complex vascular disease.

The SUPERA VERITAS system was developed by IDEV to deliver the Company's
innovative, self-expanding SUPERA(R) interwoven nitinol stent, a novel stent
platform designed for the treatment of biliary and peripheral artery disease
(PAD). Driven by an aging population, sedentary lifestyles, an increasing
prevalence of obesity and diabetes, and increased disease awareness and
screening, it is estimated that the market for devices treating peripheral
vascular disease is accelerating at a double digit annual growth rate.
Millions of patients worldwide are suffering from peripheral vascular disease
with very few treatment options available.

Professor Dierk Scheinert, M.D., Chairman of the Center for Vascular
Medicine at the Park Hospital Leipzig, Germany, said, "We have been utilizing
the SUPERA stent clinically for more than two years and we are very impressed
with the performance of the stent and positive clinical outcomes. It
represents a significant advancement in stent technology and its unique
characteristics allow physicians to treat areas where standard 'slotted tube'
nitinol stents have always encountered difficulty.

"With the new SUPERA VERITAS delivery system, we now have a more
effective tool for the smooth and controlled deployment of the SUPERA stent.
It significantly reduces the number of steps needed to prep and deliver the
stent, all of which greatly increase its ease of use and accuracy," Dr.
Scheinert added.

IDEV Chief Executive Officer Christopher M. Owens said: "The early
clinical results using our novel stent delivery system have been impressive
and have demonstrated IDEV's capacity for innovation. Physician feedback on
the new SUPERA VERITAS delivery system indicates that we have provided the
operator with a product that has improved durability, reliability, accuracy
and ease of use.

"These results have triggered significant interest in our stent. We have
been very pleased with the early acceptance of our new SUPERA VERITAS
delivery system since introducing it to a European audience at LINC 2010,"
Owens added. "We recorded a year-over-year revenue growth rate of nearly 70
percent in the first quarter of this year, and we anticipate an increasing
rate of adoption and sizeable increases in market share as the launch of our
new delivery system gains even greater traction in the market."

The Company expects to introduce two additional products in its family of
SUPERA stents by the end of this year.

Professor Thomas Zeller, M.D., of the Department of Vascular Medicine,
Heart Center in Bad Krozingen, Germany, noted that the SUPERA VERITAS
delivery system was designed to complement the flexible SUPERA stent in the
treatment of obstructive arterial disease in the superficial femoral artery
of the lower extremity.

"The introduction of the SUPERA VERITAS system substantially improves the
delivery of the innovative and unique SUPERA stent," Dr. Zeller said. "SUPERA
may be the most durable and flexible stent currently on the market for use in
treating PAD, and I believe this stent system will prove to be an important
advancement in the treatment of the disease."

The SUPERA Interwoven Self-Expanding Nitinol Stent Transhepatic Biliary
system has received 510(k) clearance for palliative treatment for biliary
strictures produced by malignant neoplasms. The SUPERA Interwoven
Self-Expanding Nitinol Stent System has received CE Mark approval in Europe
for biliary and peripheral vascular indications. The SUPERA stent is
currently the focus of a prospective, FDA-approved, single-arm clinical trial
of 258 patients at up to 40 sites in the U.S.

About IDEV Technologies, Incorporated

IDEV Technologies, Incorporated (IDEV) is an innovator and developer of
next generation medical devices for use in the interventional radiology,
vascular surgery and cardiology device marketplace. IDEV worldwide
headquarters is located in Webster, Texas with the European headquarters in
Beuningen, Netherlands.

    Contact:  Julie Nguyen, Marketing Communications Manager
              IDEV Technologies, Incorporated
              +1-281-525-2000

Julie Nguyen, Marketing Communications Manager of IDEV Technologies, Incorporated, +1-281-525-2000